|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SEPW1 |
Gene summary for SEPW1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SEPW1 | Gene ID | 6415 |
| Gene name | selenoprotein W | |
| Gene Alias | SEPW1 | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | P63302 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6415 | SEPW1 | SYSMH2 | Human | Oral cavity | OSCC | 1.27e-53 | 2.98e+00 | 0.2326 |
| 6415 | SEPW1 | SYSMH3 | Human | Oral cavity | OSCC | 2.22e-71 | 3.22e+00 | 0.2442 |
| 6415 | SEPW1 | SYSMH4 | Human | Oral cavity | OSCC | 2.62e-36 | 1.03e+00 | 0.1226 |
| 6415 | SEPW1 | SYSMH5 | Human | Oral cavity | OSCC | 6.79e-25 | 1.26e+00 | 0.0647 |
| 6415 | SEPW1 | SYSMH6 | Human | Oral cavity | OSCC | 4.95e-47 | 1.92e+00 | 0.1275 |
| 6415 | SEPW1 | Dong_P1 | Human | Prostate | Tumor | 6.52e-134 | 1.16e+00 | 0.035 |
| 6415 | SEPW1 | Dong_P3 | Human | Prostate | Tumor | 3.60e-96 | 1.19e+00 | 0.0278 |
| 6415 | SEPW1 | Dong_P4 | Human | Prostate | Tumor | 3.06e-46 | 1.14e+00 | 0.0292 |
| 6415 | SEPW1 | P7 | Human | Prostate | Tumor | 1.82e-29 | 1.25e+00 | -0.1025 |
| 6415 | SEPW1 | P9 | Human | Prostate | Tumor | 6.42e-25 | 6.20e-01 | -0.0285 |
| 6415 | SEPW1 | P10 | Human | Prostate | Tumor | 3.67e-30 | 9.51e-01 | -0.0902 |
| 6415 | SEPW1 | GSM5353215_PA_AUG_PB_1B_S2 | Human | Prostate | Tumor | 1.14e-06 | 7.50e-01 | 0.1557 |
| 6415 | SEPW1 | GSM5353217_PA_PB1A_Pool_2_S107_L004 | Human | Prostate | Tumor | 4.29e-06 | 7.73e-01 | 0.156 |
| 6415 | SEPW1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.44e-14 | 5.05e-01 | 0.1633 |
| 6415 | SEPW1 | GSM5353222_PA_PB2B_Pool_1_3_S52_L002 | Human | Prostate | Tumor | 1.32e-17 | 5.45e-01 | 0.1608 |
| 6415 | SEPW1 | GSM5353223_PA_PB2B_Pool_2_S26_L001 | Human | Prostate | Tumor | 4.78e-16 | 5.85e-01 | 0.1604 |
| 6415 | SEPW1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 8.78e-19 | 6.51e-01 | 0.1621 |
| 6415 | SEPW1 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.50e-02 | 3.16e-01 | 0.1619 |
| 6415 | SEPW1 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 1.86e-05 | 4.31e-01 | 0.159 |
| 6415 | SEPW1 | GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002 | Human | Prostate | Tumor | 3.07e-09 | 4.69e-01 | 0.1602 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |